A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).

MLA

Bonnefoi, H., et al. “A Phase II Trial of Abiraterone Acetate plus Prednisone in Patients with Triple-Negative Androgen Receptor Positive Locally Advanced or Metastatic Breast Cancer (UCBG 12-1).” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 27, no. 5, May 2016, pp. 812–18. EBSCOhost, https://doi.org/10.1093/annonc/mdw067.

APA

Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L’Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., Mousseau, M., Dauba, J., Del Piano, F., Desmoulins, I., Coussy, F., Madranges, N., Grenier, J., Bidard, F. C., Proudhon, C., … Gonçalves, A. (2016). A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1). Annals of Oncology : Official Journal of the European Society for Medical Oncology, 27(5), 812–818. https://doi.org/10.1093/annonc/mdw067

Chicago

Bonnefoi, H, T Grellety, O Tredan, M Saghatchian, F Dalenc, A Mailliez, T L’Haridon, et al. 2016. “A Phase II Trial of Abiraterone Acetate plus Prednisone in Patients with Triple-Negative Androgen Receptor Positive Locally Advanced or Metastatic Breast Cancer (UCBG 12-1).” Annals of Oncology : Official Journal of the European Society for Medical Oncology 27 (5): 812–18. doi:10.1093/annonc/mdw067.